Immunic, Inc.

NasdaqGS:IMUX Stock Report

Market Cap: US$70.3m

Immunic Future Growth

Future criteria checks 2/6

Immunic is forecast to grow earnings and revenue by 52.8% and 83.7% per annum respectively while EPS is expected to grow by 53% per annum.

Key information

52.8%

Earnings growth rate

52.98%

EPS growth rate

Biotechs earnings growth23.8%
Revenue growth rate83.7%
Future return on equityn/a
Analyst coverage

Good

Last updated15 Dec 2025

Recent future growth updates

Recent updates

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Oct 17
We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 09

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 28

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Oct 25
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22
Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13
Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27
Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Immunic stock gains on $60M oversubscribed PIPE financing

Oct 10

Immunic GAAP EPS of -$0.72 in-line

Aug 04

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Jul 27
Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Apr 13
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Dec 24
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

Aug 13
Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely

May 10
We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

NasdaqGS:IMUX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202717-117-111-1178
12/31/202611-109-120-689
12/31/2025N/A-104-98-869
9/30/2025N/A-103-90-89N/A
6/30/2025N/A-102-90-90N/A
3/31/2025N/A-96-83-83N/A
12/31/2024N/A-101-85-85N/A
9/30/2024N/A-97-76-76N/A
6/30/2024N/A-95-73-72N/A
3/31/2024N/A-98-76-75N/A
12/31/2023N/A-94-71-71N/A
9/30/2023N/A-129-72-72N/A
6/30/2023N/A-127-68-68N/A
3/31/2023N/A-125-64-64N/A
12/31/2022N/A-120-65-65N/A
9/30/2022N/A-85-74-74N/A
6/30/2022N/A-83-78-78N/A
3/31/2022N/A-79-91-91N/A
12/31/2021N/A-93-83-83N/A
9/30/2021N/A-83-74-74N/A
6/30/2021N/A-77-68-68N/A
3/31/2021N/A-70-48-48N/A
12/31/2020N/A-44-46-46N/A
9/30/2020N/A-41-39-38N/A
6/30/2020N/A-36-33-32N/A
3/31/2020N/A-39-34-34N/A
12/31/2019N/A-35-29-29N/A
9/30/2019N/A-32-26-26N/A
6/30/2019N/A-26N/A-22N/A
3/31/2019N/A-14N/A-13N/A
12/31/2018N/A-12N/A-10N/A
9/30/2018N/A-10N/A-10N/A
12/31/2017N/A-10N/A-10N/A
12/31/20160-1N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMUX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMUX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMUX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMUX's revenue (83.7% per year) is forecast to grow faster than the US market (10.7% per year).

High Growth Revenue: IMUX's revenue (83.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IMUX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 09:33
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunic, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets